Get the Stockscreener App
11.78
3.60%
-0.44
Personalis Inc stock is traded at $11.78, with a volume of 2.90M.
It is down -3.60% in the last 24 hours and up +3.70% over the past month.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. The company' products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
See More
Previous Close:
$12.22
Open:
$12.34
24h Volume:
2.90M
Relative Volume:
0.77
Market Cap:
$1.26B
Revenue:
$64.52M
Net Income/Loss:
$-95.55M
P/E Ratio:
-11.58
EPS:
-1.0169
Net Cash Flow:
$-84.65M
1W Performance:
-23.46%
1M Performance:
+3.70%
6M Performance:
+15.83%
1Y Performance:
+75.56%
1-Day Range:
$11.73
$12.63
1-Week Range:
$11.73
$14.75
52-Week Range:
$3.84
$16.39
Personalis Inc Stock (PSNL) Company Profile
Name
Personalis Inc
Sector
Industry
Phone
650-752-1300
Address
6600 DUMBARTON CIRCLE, FREMONT, CA
Compare PSNL vs TMO, DHR, IDXX, A, NTRA
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PSNL
Personalis Inc
|
11.78 | 1.26B | 64.52M | -95.55M | -84.65M | -1.0169 |
TMO
Thermo Fisher Scientific Inc
|
568.26 | 211.18B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
191.50 | 134.62B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
544.32 | 42.94B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
138.57 | 39.14B | 7.23B | 1.41B | 1.09B | 4.979 |
NTRA
Natera Inc
|
261.99 | 37.52B | 2.50B | -226.32M | 71.51M | -1.6412 |
Personalis Inc Stock (PSNL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-25 | Resumed | Morgan Stanley | Equal-Weight |
| May-15-25 | Initiated | Guggenheim | Buy |
| Mar-17-25 | Initiated | Craig Hallum | Buy |
| Feb-06-23 | Upgrade | Needham | Hold → Buy |
| Jan-07-22 | Upgrade | BofA Securities | Neutral → Buy |
| Nov-05-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-03-21 | Downgrade | Needham | Buy → Hold |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Sep-20-21 | Reiterated | Needham | Buy |
| May-06-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-28-21 | Initiated | Truist | Buy |
| Jan-04-21 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-12-20 | Reiterated | Needham | Buy |
| Nov-06-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Oct-19-20 | Initiated | Citigroup | Buy |
| Oct-08-20 | Initiated | BTIG Research | Buy |
| Aug-27-20 | Initiated | H.C. Wainwright | Buy |
| Aug-18-20 | Initiated | Needham | Buy |
| Sep-26-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jul-15-19 | Initiated | BofA/Merrill | Neutral |
| Jul-15-19 | Initiated | Cowen | Outperform |
| Jul-15-19 | Initiated | Morgan Stanley | Overweight |
| Jul-15-19 | Initiated | Oppenheimer | Outperform |
View All
Personalis Inc Stock (PSNL) Latest News
Tempus to acquire Personalis in $1.5 billion deal to expand MRD capabilities - DOTmed
Personalis Inc (PSNL) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Kalpesh Patel: The Fifth MRD Buyout in Less Than a Year - Oncodaily
Why Is PSNL Stock Up 5% After-Hours? - Stocktwits
Why Personalis Stock Is Rising: Medicare Covers Lung Cancer MRD Test - Stocktwits
Tempus makes $1.5B bet to corner cancer-test market - thestreet.com
Tempus AI Makes Billion-Dollar Bet on the Future of Cancer Monitoring - Sahm
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Personalis, Inc. (Nasdaq – PSNL), Distribution Solutions Group, Inc. (Nasdaq – DSGR), Cross Country Healthcare, Inc. (Nasdaq – CCRN), Nuvalent, Inc. (Nasd - Supply Chain Digital
Tempus AI to Acquire Cancer Diagnostics Firm Personalis for approximately $1.5 Billion, Targeting MRD Market Leadership - finance.biggo.com
Personalis (PSNL) Proxy filing Summary - Quartr
Tempus AI (TEM) On Its Personalis Deal And Whether The Bull Case Is Priced In - Yahoo Finance
Personalis Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Personalis, Inc.PSNL - The AI Journal
Cathie Wood’s Tempus AI Bet Is Bleeding — And the Chart Looks Worse Than Wall Street Thinks - Sahm
Tempus to acquire Personalis, Inc. (PSNL) in cash and stock merger - Stock Titan
BTIG Maintains Personalis(PSNL.US) With Buy Rating, Raises Target Price to $16.25 - Moomoo
Why Is Tempus AI Stock Volatile Tuesday?Personalis (NASDAQ:PSNL), Tempus AI (NASDAQ:TEM) - Benzinga
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Personalis, Inc. (NASDAQ: PSNL) - Morningstar
Tempus AI buys Personalis for $1.5 billion - grafa.com
Personalis: Tempus Bought The Best Part Of The Story (NASDAQ:PSNL) - Seeking Alpha
Tempus AI Buys Personalis for $1.5B to Boost Cancer Monitoring - Medical Device and Diagnostic industry
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
Tempus AI to Acquire Personalis for $1.5 Billion to Expand Precision Oncology Platform - HLTH
Tempus AI is acquiring cancer-monitoring firm Personalis in a $1.5 billion stock deal - qz.com
Tempus AI Acquires Personalis: Why Both Stocks Are A Buy Now (NASDAQ:TEM) - Seeking Alpha
Tempus AI acquires cancer-monitoring firm Personalis for $1.5 billion - Yahoo Finance
Tempus to acquire Personalis - Medical Buyer
Tempus AI acquires Personalis in $1.5bn precision oncology-focused deal - Yahoo Finance
Tempus AI snaps up genomics partner Personalis for $1.5 billion - The Pharma Letter
Tempus AI (TEM) to Acquire Personalis in Strategic Move - GuruFocus
Tempus AI (TEM) Is Buying Personalis For $1.5 Billion To Deepen Cancer Monitoring - Yahoo Finance
AI healthcare company acquires US biotech firm for USD 1.7bn - medwatch.com
Personalis (PSNL) Registration Filing Summary - Quartr
TEM, PSNL stocks are falling — why Morgan Stanley still likes Tempus AI’s Personalis deal - MSN
Personalis, Inc. (PSNL) Tempus AI, Inc.M&A CallSlideshow (NASDAQ:PSNL) 2026-07-20 - Seeking Alpha
Daily Brief Health Care: Personalis Inc, ResMed Inc, Ascentage Pharma, Apnimed, UltraGreen.ai, Horizon Quantum Holdings, Scribe Therapeutics and more - Smartkarma
Daily Brief United States: Meta, Gold, Braemar Hotels & Resorts , AIOS, Alarm.Com Holdings, Personalis Inc, Arcbest Corp, New Horizon Aircraft, Jersey Mike's Subs, Crude Oil and more - Smartkarma
Personalis Price Target Announced at $16.25/Share by Lake Street - Moomoo
AI-Driven Tempus Acquires Cancer Diagnostics Firm Personalis for $1.7B in Stock - Briefs Finance
Tempus AI Buys Personalis for $1.5 Billion, and Both Stocks Sink -- Barrons.com - Moomoo
Tempus AI Acquires Personalis For $1.5bn To Expand MRD Cancer Testing - insights.citeline.com
Tempus AI (TEM) plans stock-plus-cash merger with Personalis (PSNL) - Stock Titan
Tempus AI (PSNL partner) to buy Personalis in $1.5B premium stock acquisition - Stock Titan
Tempus to buy cancer test maker Personalis for $1.5 billion - 102.7 WBOW
Tempus AI Announces Merger Agreement to Acquire Personalis - TipRanks
Tempus AI Buys Personalis in $1.7 Billion Precision Oncology Dea - GuruFocus
Expecting Massive Test Growth in Cancer & More, Tempus AI Strikes $1.5B Deal to Buy Personalis - MedCity News
Needham cuts Personalis stock rating on Tempus AI acquisition By Investing.com - Investing.com South Africa
Tempus finds time right for $1.5B Personalis MRD grab - BioWorld News
Tempus AI Buys Personalis in $1.7 Billion Precision Oncology Deal - TradingView
Latham & Watkins Advises Tempus AI on US$1.5 Billion Acquisition of Personalis - Latham & Watkins LLP
Personalis Acquisition Price Warranted by Growth Prospects, Needham Says - Moomoo
Personalis Inc Stock (PSNL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Personalis Inc Stock (PSNL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Chen Richard | President and CMO |
Jul 15 '26 |
Sale |
15.15 |
100,000 |
1,515,000 |
173,880 |
0.02%
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):